Latest News on XRAY

Financial News Based On Company


Advertisement
Advertisement

Dental equipment & technology stocks Q3 highlights: Dentsply Sirona

https://www.tradingview.com/news/stockstory:5382890ee094b:0-dental-equipment-technology-stocks-q3-highlights-dentsply-sirona/
The dental equipment and technology sector reported a softer Q3, with revenues generally in line with analyst estimates but next quarter's guidance falling short. Dentsply Sirona (NASDAQ:XRAY) had the weakest performance, missing revenue and EPS estimates, while Envista Holdings (NVST) saw solid results despite a market downturn. Align Technology (ALGN) exceeded revenue expectations but offered disappointing guidance, and Henry Schein (HSIC) met expectations with strong revenue growth.

UBS maintains Dentsply Sirona at Buy, lowers price target to $13 from $17

https://www.tradingview.com/news/tradingview:2aba84c5932fe:0-ubs-maintains-dentsply-sirona-at-buy-lowers-price-target-to-13-from-17/
UBS has reiterated its "Buy" rating for Dentsply Sirona (XRAY) but has reduced its price target from $17 to $13, a 23.5% decrease. This new price target suggests a potential upside of 41.9% from the stock's closing price of $9.16 on November 13. Other recent analyst actions on Dentsply Sirona have set price targets ranging from $10 to $13.

How Dentsply Sirona Inc. (XRAY) Affects Rotational Strategy Timing

https://news.stocktradersdaily.com/news_release/14/How_Dentsply_Sirona_Inc._XRAY_Affects_Rotational_Strategy_Timing_111426111001_1794672601.html
Dentsply Sirona Inc. (XRAY) is showing near-term weak sentiment within a broader long-term weak bias, despite mid-term strength. Quantitative analysis highlights an exceptional 80.5:1 risk-reward setup, targeting an 18.7% gain against a 0.2% risk. Three distinct AI-generated trading strategies are provided, including position trading (long), momentum breakout (breakout), and risk hedging (short), each with specific entry, target, and stop-loss levels.

Tax withholding leaves DENTSPLY SIRONA (XRAY) executive with 43,482 directly held shares.

https://www.stocktitan.net/sec-filings/XRAY/form-4-dentsply-sirona-inc-insider-trading-activity-15312202cd50.html
Lindi Rene Barton-Brobst, SVP, GC & Secretary of DENTSPLY SIRONA Inc. (XRAY), had 1,704 shares withheld on November 11, 2026, to cover taxes related to the vesting of her Restricted Stock Units and dividend equivalent units. Following this transaction, her direct holdings amounted to 43,482 shares, with an additional 255 shares held indirectly through a 401(k). This insider trading activity was reported in an SEC Form 4 filing.

DENTSPLY SIRONA Inc. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts

https://simplywall.st/stocks/us/healthcare/nasdaq-xray/dentsply-sirona/news/dentsply-sirona-inc-reported-a-surprise-loss-and-analysts-ha
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) reported a surprise loss in its latest quarterly results, with revenues missing analyst predictions and a statutory loss of US$0.01 per share. Following these results, analysts have revised their 2027 forecasts, maintaining revenue estimates but significantly reducing EPS expectations. This bearish shift led to a 9.4% drop in the consensus price target to US$11.23, reflecting concerns about the company's future valuation.
Advertisement

Dentsply Sirona stock trades at 8.49 euros in Saturday session

https://www.ad-hoc-news.de/boerse/news/corporate-news/dentsply-sirona-stock-trades-at-8-49-euros-in-saturday-session/70477352
Dentsply Sirona stock was quoted at 8.49 euros on Lang & Schwarz during a Saturday session, providing a reference point for investors. The company had previously scheduled its third-quarter update for November 5, which remains a key earnings milestone. This weekend quote offers investors insight into the US dental-equipment company ahead of the resumption of regular trading.

Dentsply Sirona (XRAY) stock trades down, here is why

https://www.tradingview.com/news/stockstory:923c86cd1094b:0-dentsply-sirona-xray-stock-trades-down-here-is-why/
Shares of Dentsply Sirona (XRAY) fell 7% after the company reported a GAAP diluted loss per share for the third quarter of 2026 and lowered its full-year financial outlook, missing Wall Street estimates. The market views this news as meaningful, although it doesn't fundamentally change the perception of the business. Despite recent volatility and a prior gain due to eased regulatory uncertainty, the stock is down 17.4% year-to-date and significantly below its 52-week high.

Dentsply Sirona stock hits 52-week low at 8.21 USD

https://www.investing.com/news/company-news/dentsply-sirona-stock-hits-52week-low-at-821-usd-93CH-5008596
Dentsply Sirona Inc.'s stock recently dropped to a 52-week low of $8.21, although its current price of $8.25 is slightly above its 52-week low of $8.32. Despite a 7.11% decline over the past year, the stock shows signs of recovery with a 5.88% gain in the last week and is considered undervalued with a Fair Value of $14.74. The company maintains a 6.34% dividend yield and has sustained dividend payments for 32 consecutive years, even after reporting Q3 2026 financial results that missed Wall Street expectations with adjusted EPS of $0.29 and revenue of $836 million.

Dentsply Sirona (XRAY) stock trades down, here is why

https://markets.financialcontent.com/stocks/article/stockstory-2026-11-6-dentsply-sirona-xray-stock-trades-down-here-is-why
Dentsply Sirona (NASDAQ: XRAY) shares dropped 7% after the company reported a GAAP diluted loss per share for Q3 2026 and lowered its full-year financial outlook, missing Wall Street estimates. The company's net sales were $836 million, with a GAAP diluted loss of $0.01 per share. Dentsply Sirona now forecasts full-year 2026 net sales of approximately $3.5 billion and adjusted earnings per share between $1.20 and $1.30.

Market Challenges and Margin Pressure Weigh on Dentsply's Near-Term Results

https://www.morningstar.com/company-reports/1508883-market-challenges-and-margin-pressure-weigh-on-dentsplys-near-term-results
Dentsply Sirona, a major dental equipment manufacturer, faces market challenges and margin pressure, leading to lowered guidance and uncertain recovery timing. The company is adapting by investing in its Cerec chairside workflow system and expanding partnerships to open up its historically closed system and broaden its end markets. This strategic shift aims to help Dentsply compete in an increasingly fragmented market.
Advertisement

DENTSPLY SIRONA (NASDAQ:XRAY) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS

https://www.marketbeat.com/instant-alerts/earnings-dentsply-sirona-nasdaq-xray-announces-quarterly-earnings-results-misses-expectations-by-002-eps-2026-11-05/
DENTSPLY SIRONA (NASDAQ:XRAY) announced its quarterly earnings, reporting $0.29 EPS, missing analysts' consensus of $0.31, and revenue of $836 million, below estimates of $861.68 million. The company also cut its FY 2026 guidance for adjusted EPS to $1.20–$1.30 and sales to approximately $3.5 billion. Following the announcement, XRAY stock traded down 5.3%, hitting $10.09.

Dentsply Sirona Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62958399/dentsply-sirona-q3-2026-earnings-call-transcript
Dentsply Sirona reported Q3 2026 revenue of $836 million, a 7.6% decline, and lowered its full-year net sales outlook to $3.5 billion with adjusted EPS between $1.20 and $1.30. The company is advancing its Return to Growth Action Plan by investing in clinical education, sales force expansion, and product innovation, showing early successes in Wellspect Healthcare and U.S. value implants and endodontic products. Management emphasized improved financial visibility, cost management, and debt reduction as key priorities moving forward.

Dentsply Sirona (NASDAQ:XRAY) misses Q3 2026 revenue estimates, stock drops 14.4%

https://uk.finance.yahoo.com/news/dentsply-sirona-nasdaq-xray-misses-212919849.html
Dentsply Sirona (NASDAQ:XRAY) reported Q3 2026 revenue of $836 million, missing analysts' consensus estimates by 2.7% and representing a 7.5% year-on-year decline. The company also missed adjusted EPS estimates and lowered its full-year revenue and adjusted EPS guidance, leading to a 14.4% drop in its stock price. Despite these setbacks, the CEO noted progress in their "Return-to-Growth Action Plan."

Dentsply International (XRAY) Q3 Earnings and Revenues Miss Estimates

https://finance.yahoo.com/markets/stocks/articles/dentsply-international-xray-q3-earnings-214505003.html
Dentsply International (XRAY) reported Q3 earnings of $0.29 per share, missing the Zacks Consensus Estimate of $0.30, and revenues of $836 million, falling short of the $856 million estimate. The dental products manufacturer has surpassed EPS estimates only once in the last four quarters and has a Zacks Rank #4 (Sell), indicating expected underperformance in the near future. The stock has lost 6.8% year-to-date, lagging the S&P 500's 12.3% gain.

Form 8-K DENTSPLY SIRONA Inc. For: Nov 05

https://www.streetinsider.com/SEC+Filings/Form+8-K+DENTSPLY+SIRONA+Inc.+For%3A+Nov+05/27300476.html
DENTSPLY SIRONA Inc. filed a Form 8-K with the SEC on November 5, 2026, reporting its financial results for the third fiscal quarter ended September 30, 2026. This report includes a press release (Exhibit 99.1) detailing these results. The company's common stock is traded on The Nasdaq Stock Market LLC under the symbol XRAY.
Advertisement

Dentsply Sirona Reports Third Quarter 2026 Results

https://www.globenewswire.com/news-release/2026/11/05/3396986/0/en/dentsply-sirona-reports-third-quarter-2026-results.html
Dentsply Sirona announced its third-quarter 2026 financial results, with net sales of $836 million and an adjusted EPS of $0.29. Despite challenging industry conditions, the company reported progress on its "Return-to-Growth Action Plan," including record sales for Wellspect Healthcare and advancements in implants and endodontics. The full-year 2026 outlook has been updated to approximately $3.5 billion in net sales and an adjusted EPS of $1.20 to $1.30.

DENTSPLY SIRONA to Post Q3 Earnings: What's in Store for the Stock?

https://www.tradingview.com/news/zacks:8f10cac39094b:0-dentsply-sirona-to-post-q3-earnings-what-s-in-store-for-the-stock/
DENTSPLY SIRONA (XRAY) is set to release its third-quarter 2026 results on November 5. The company is expected to have faced operational headwinds and subdued demand, partially offset by progress in its Return-to-Growth Action Plan. The Zacks Consensus Estimate projects revenues of $856 million and earnings of 30 cents per share, but the Zacks Model does not conclusively predict an earnings beat.

Dentsply Sirona (XRAY) Q3 earnings report preview: what to look for

https://www.tradingview.com/news/stockstory:c51fec72c094b:0-dentsply-sirona-xray-q3-earnings-report-preview-what-to-look-for/
Dentsply Sirona (XRAY) is preparing to release its Q3 earnings report this Thursday afternoon. Analysts expect a 4.9% year-on-year revenue decline, consistent with the previous year, though the company generally beats Wall Street estimates. Peer results from Henry Schein and Align Technology offer some insight, and investor sentiment in the healthcare equipment and supplies segment has been positive, with Dentsply Sirona's stock up 14.1% in the last month.

DENTSPLY SIRONA (XRAY) Stock May Be Undervalued Following Fiduciary Duty Investigation

https://uk.finance.yahoo.com/news/dentsply-sirona-xray-stock-may-042723974.html
DENTSPLY SIRONA (XRAY) shares may be undervalued, trading at a P/S ratio of 0.5x compared to an industry average of 2.7x, despite an ongoing investigation into potential breaches of fiduciary duty. The stock's valuation is heavily scrutinized after an 80.4% price drop over five years, prompting investors to assess if current sales justify its US$9.90 price. Analysts and community narratives are split, with some seeing a durable dental platform and others concerned about revenue pressure and growth prospects.

DENTSPLY SIRONA Inc. (XRAY.VI) Seasonal returns chart

https://uk.finance.yahoo.com/quote/XRAY.VI/seasonality/
The article provides a seasonal returns chart for DENTSPLY SIRONA Inc. (XRAY.VI), showing average monthly price returns from 2017 to 2026. It also notes that the Q3 2026 earnings call for XRAY.VI is scheduled for November 5, 2026, at 22:30 CET. The current stock price for DENTSPLY SIRONA Inc. (XRAY.VI) is 8.86, up 3.02%.
Advertisement

DENTSPLY SIRONA Inc. (XRAY) Stock forecasts

https://uk.finance.yahoo.com/research/reports/ARGUS_4359_QuantitativeReport_1768953600000
Dentsply Sirona is a major global manufacturer of dental equipment and supplies. An Argus report from January 21, 2026, lowered the target price for XRAY to $11.00, with the current price at $9.44. The report provides a quantitative analysis and earnings estimate for the healthcare sector company.

Dentsply Sirona hosts 2026 MIS Education Forum

https://www.drbicuspid.com/clinical/implants/article/15838312/dentsply-pharmaceutical-dentsply-sirona-hosts-2026-mis-education-forum
Dentsply Sirona will host its 2026 MIS Education Forum on November 13-14 at the Dentsply Sirona Academy in Charlotte, NC. The two-day program will focus on "Simplifying Implant Success Through Science, Innovation & Clinical Excellence," offering lectures, hands-on training, and peer-to-peer exchange with a restorative-driven approach to implant dentistry. Topics will cover digital workflows, aesthetic strategies, full-arch rehabilitation, and managing complications.

Did Dentsply Sirona Inc. Insiders Breach their Fiduciary Duties to Shareholders?

https://www.morningstar.com/news/pr-newswire/20261027ny82372/did-dentsply-sirona-inc-insiders-breach-their-fiduciary-duties-to-shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Dentsply Sirona Inc. (NASDAQ: XRAY) breached their fiduciary duties to shareholders. The firm encourages Dentsply stockholders to contact them to discuss their legal rights and options, which may include seeking corporate governance reforms, the return of funds to the company, or financial incentive awards. Halper Sadeh LLC emphasizes that shareholder involvement can enhance corporate transparency, accountability, and overall value.

Dentsply Sirona reports five years of sustainability progress and sets 2030 targets

https://www.dental-tribune.com/c/dentsply-sirona/news/dentsply-sirona-reports-five-years-of-sustainability-progress-and-sets-2030-targets/
Dentsply Sirona has reported significant progress five years after launching its "BEYOND" sustainability strategy, centered on Healthy Planet, Healthy Smiles, and Healthy Business. The company has exceeded several 2025 targets, including emissions reduction and enabling millions of smiles. Building on this success, Dentsply Sirona has announced new ambitious goals for 2030, such as further reducing greenhouse gas emissions by 42%, transitioning manufacturing sites to 100% renewable electricity, and enabling an additional 30 million smiles.

Barrington Research Issues Pessimistic Forecast for DENTSPLY SIRONA (NASDAQ:XRAY) Stock Price

https://www.marketbeat.com/instant-alerts/analyst-barrington-research-issues-pessimistic-forecast-for-dentsply-sirona-nasdaq-xray-stock-price-2026-10-26/
Barrington Research has lowered its price target for DENTSPLY SIRONA (NASDAQ:XRAY) from $15 to $13, while maintaining an "outperform" rating, indicating a potential upside of approximately 38%. Despite beating quarterly earnings and revenue estimates, the company's stock has declined due to weak fundamentals, including a 4.1% year-over-year revenue decrease and a negative net margin. Analyst sentiment for DENTSPLY SIRONA remains mixed, with a consensus "Hold" rating and an average price target of $12.62.
Advertisement

DENTSPLY SIRONA Inc. Estimates – NASDAQ:XRAY

https://www.tradingview.com/symbols/NASDAQ-XRAY/financials-estimates/
The article provides an overview of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) financial estimates and actuals available on TradingView. It highlights various financial data points such as income statement, balance sheet, cash flow, and valuation metrics, allowing users to compare reported results with analyst estimates. The platform also offers tools for visualizing financial trends over time.

DENTSPLY SIRONA, Inc. Estimates – EUROTLX:4XRAY

https://www.tradingview.com/symbols/EUROTLX-4XRAY/financials-estimates/
This article provides an overview of DENTSPLY SIRONA, Inc. (EUROTLX:4XRAY) financials and analyst estimates on TradingView. It directs users to explore reported financial data and compare actual results with average, high, and low estimates across various financial statements. The page serves as a financial data hub for the company's stock.

Mizuho Securities Maintains Dentsply Sirona(XRAY.US) With Hold Rating, Cuts Target Price to $12

https://www.moomoo.com/news/post/1002017158/mizuho-securities-maintains-dentsply-sirona-xrayus-with-hold-rating-cuts
Mizuho Securities has maintained a Hold rating on Dentsply Sirona (XRAY.US) while reducing its target price for the stock from $15 to $12. This adjustment reflects an updated outlook from the firm regarding the company's valuation.

XRAY Maintained by Mizuho -- Price Target Lowered to $12.00

https://www.gurufocus.com/news/9136509/xray-maintained-by-mizuho-price-target-lowered-to-1200
Mizuho has maintained a 'Neutral' rating on Dentsply Sirona (XRAY) but lowered its price target from $14.00 to $12.00, reflecting concerns about the company's near-term performance. Despite being significantly undervalued according to GuruFocus's GF Value, Dentsply Sirona exhibits average financial performance with weaknesses in growth and momentum, suggesting potential challenges for investors.

DENTSPLY SIRONA (NASDAQ:XRAY) Stock Price Target Lowered at Mizuho

https://www.marketbeat.com/instant-alerts/analyst-dentsply-sirona-nasdaq-xray-stock-price-target-lowered-at-mizuho-2026-10-22/
Mizuho has lowered its price target for DENTSPLY SIRONA (NASDAQ:XRAY) from $14 to $12, maintaining a "neutral" rating on the stock, with the new target implying a 32.16% upside. Despite a mixed analyst sentiment, the consensus rating remains "Hold" with an average price target of $12.77. The company recently exceeded earnings expectations, reporting an EPS of $0.52 against a $0.35 consensus, though revenue declined by 4.1% year-over-year.
Advertisement

DENTSPLY SIRONA Inc. $XRAY Shares Sold by Cooke & Bieler LP

https://www.marketbeat.com/instant-alerts/filing-dentsply-sirona-inc-xray-shares-sold-by-cooke-bieler-lp-2026-10-22/
Cooke & Bieler LP significantly reduced its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 26.5% in the third quarter, selling 1.84 million shares but still retaining over 5 million shares worth approximately $45.1 million. Despite high institutional ownership, analyst sentiment is mixed, with the stock holding an average "Hold" rating and a consensus price target of $12.92, while trading near its one-year low. The company recently reported better-than-expected earnings for the last quarter.

A Dentsply Sirona webcast will review third-quarter results on Nov. 5.

https://www.stocktitan.net/news/XRAY/dentsply-sirona-to-host-third-quarter-2026-conference-call-on-5o1bo6f16sza.html
Dentsply Sirona (XRAY) will host a conference call and live webcast on November 5, 2026, at 4:30 p.m. EST to discuss its third-quarter 2026 financial results. Earnings materials will be available on the company's investor website prior to the call, where access details and a replay will also be provided. The company, headquartered in Charlotte, North Carolina, is a leading manufacturer of professional dental products and technologies.

Dentsply Sirona Q3FY26 Results: Earnings call set for November 5

https://scanx.trade/stock-market-news/companies/dentsply-sirona-q3fy26-results-earnings-call-set-november-5/54073503
Dentsply Sirona Inc. is scheduled to host an investor conference call and live webcast on November 5, 2026, at 4:30 pm EST to discuss its third-quarter 2026 financial results. Financial materials will be available on the company's investor website before the call, and a webcast replay will be accessible afterward. The company, headquartered in Charlotte, North Carolina, is a diversified manufacturer of professional dental products and technologies.

Dentsply Sirona to Host Third Quarter 2026 Conference Call on November 5

https://www.globenewswire.com/news-release/2026/10/20/3384970/0/en/dentsply-sirona-to-host-third-quarter-2026-conference-call-on-november-5.html
Dentsply Sirona (Nasdaq: XRAY) announced it will host an investor conference call and live webcast on Thursday, November 5, 2026, at 4:30 p.m. EST to discuss its third-quarter 2026 financial results. Financial earnings materials will be available on the company's investor relations website prior to the call. A webcast replay will also be accessible on the website after the event.

Leerink cuts Dentsply Sirona target from USD 14 to USD 10 for Dentsply Sirona stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/leerink-cuts-dentsply-sirona-target-from-usd-14-to-usd-10-for-dentsply-sirona-stock/70372674
Leerink Partners has lowered its price target for Dentsply Sirona (XRAY) from USD 14 to USD 10, following a broader reassessment by analysts and mixed second-quarter results. Dentsply Sirona's Q2 2026 revenue fell 4.10 percent year-over-year to USD 898.0 million, although the company returned to profitability with a net income of USD 37.0 million. The market awaits further developments, including the expansion of its technology portfolio distribution and upcoming September 2026 earnings report.
Advertisement

Dentsply Sirona to Host Third Quarter 2026 Conference Call on November 5

https://finance.yahoo.com/markets/stocks/articles/dentsply-sirona-host-third-quarter-201500515.html
Dentsply Sirona announced it will host an investor conference call and live webcast on Thursday, November 5, 2026, at 4:30 p.m. EST to discuss its third quarter 2026 financial results. Financial earnings materials and webcast details will be available on the Investors section of the Company's website. Dentsply Sirona is a leading global manufacturer of professional dental products and technologies, headquartered in Charlotte, North Carolina.

XRAY6094731 Bond Profile: Coupon and Redemption

https://www.tradingview.com/symbols/FINRA-XRAY6094731/profile/
This article provides a detailed profile of the DENTSPLY SIRONA Inc. bond, XRAY6094731, outlining its key facts, classification, credit risk assessment, and interest payment schedule. It specifies the bond's issuer, issue and maturity dates, face value, and minimum denomination, along with its fixed semi-annual coupon rate and upcoming coupon payouts. The profile also includes information on the bond's outstanding amount and redemption type.

Leerink cuts target for Dentsply Sirona stock to USD 10.00

https://www.ad-hoc-news.de/boerse/news/nebenwerte/leerink-cuts-target-for-dentsply-sirona-stock-to-usd-10-00/70353292
Leerink has reduced its price target for Dentsply Sirona (XRAY) stock to USD 10.00 from USD 14.00, maintaining a Market Perform rating. This revision follows a 4.10% year-over-year decline in Q2 revenue and ahead of the upcoming Q3 earnings report on November 5, 2026. The analyst's move places focus on the company's turnaround plan, recent expanded dealer partnerships, and whether these initiatives can offset the sales decline.

DENTSPLY SIRONA Inc. (XRAY) Stock forecasts

https://au.finance.yahoo.com/research/reports/ARGUS_4359_QuantitativeReport_1791936000000
Dentsply Sirona is a leading global manufacturer of dental equipment and supplies. An Argus report from October 14, 2026, provides analysis on the company's stock, XRAY, without specifying a rating or earnings estimate in this excerpt. The current price is $8.57, but the full report is needed for a complete price target and detailed insights.

Leerink cuts target for Dentsply Sirona stock from USD 14.00 to USD 10.00

https://www.ad-hoc-news.de/boerse/news/nebenwerte/leerink-cuts-target-for-dentsply-sirona-stock-from-usd-14-00-to-usd-10-00/70329544
Leerink has lowered its price target for Dentsply Sirona (XRAY) stock from $14.00 to $10.00, while maintaining a Market Perform rating due to limited expectations for a strong quarter and broader demand concerns. The company reported a 4.10% year-over-year decrease in Q2 revenue to $898.0 million, though adjusted EPS remained at $0.52 and operating cash flow increased significantly. Dentsply Sirona is focused on a turnaround, with an expanded dealer partnership scheduled to begin November 1, 2026, to offer its technology portfolio.
Advertisement

Dentsply Sirona stock hits 52-week low at 8.38 USD By Investing.com

https://ca.investing.com/news/stock-market-news/dentsply-sirona-stock-hits-52week-low-at-838-usd-93CH-4881197
Dentsply Sirona (XRAY) stock has fallen to a 52-week low of $8.38, marking a 34.38% decrease over the past year and a 26% year-to-date loss. Despite the decline, InvestingPro analysis suggests the stock is undervalued within the healthcare equipment sector, with analysts expecting a return to profitability this year and offering a 7.5% dividend yield. The company recently reported Q2 revenue of $898 million, beating estimates, but sales were down year-over-year.

XRAY Maintains Rating by Leerink Partners -- Price Target Lowered to $10

https://www.gurufocus.com/news/9124136/xray-maintains-rating-by-leerink-partners-price-target-lowered-to-10
Leerink Partners has maintained its "Market Perform" rating on Dentsply Sirona (XRAY) but significantly lowered its price target from $14.00 to $10.00, reflecting a cautious outlook due to the company's profitability challenges. Despite XRAY appearing 51.1% undervalued according to its GF Value™ of $17.26 against a current price of $8.44, its GF Score™ of 54/100 and low growth potential suggest it may be a "Possible Value Trap, Think Twice." Gurus show mixed sentiment with some adding and others trimming positions, while insiders have shown no recent buying or selling activity.

Dentsply Sirona Inc Share Price - XRAY, RNS News, Articles, Quotes, & Charts (NASDAQ:XRAY)

https://www.proactiveinvestors.com/companies/5933/Dentsply-Sirona-Inc
This page provides current share price information, news, quotes, and charts for Dentsply Sirona Inc (NASDAQ: XRAY). It details the company's market data, including its market capitalization, 52-week high and low, and offers a brief overview of its operations as the world's largest manufacturer of professional dental products.

Dentsply Sirona Expands U.S. Digital Dentistry Reach With Midwest Deal

https://fr.tradingview.com/news/zacks:03bfd2990094b:0-dentsply-sirona-expands-u-s-digital-dentistry-reach-with-midwest-deal/
Dentsply Sirona has expanded its U.S. commercial reach through an enhanced distribution agreement with Midwest Dental Equipment & Supply, effective November 1, 2026. This partnership will extend access to Dentsply Sirona’s digital dentistry technology, aiming to improve efficiency and support growth for dental practices. The deal is the company's seventh North American dealer partnership enhancement this year and is expected to create additional sales opportunities.

Piper Sandler maintains Neutral rating on Dentsply Sirona, $12 price target

https://www.tradingview.com/news/tradingview:7721a8453359b:0-piper-sandler-maintains-neutral-rating-on-dentsply-sirona-12-price-target/
Piper Sandler has reiterated a Neutral rating on Dentsply Sirona (XRAY) but lowered its price target from $14 to $12, implying a 38.1% upside from the October 8 close. This conservative outlook is due to weak growth projections, with an anticipated organic growth of only 2% for 2028 and a diluted EPS forecast of $1.53, reflecting a broader market rotation and a significant stock decline.
Advertisement

Dentsply Sirona (XRAY): Buy, Sell, or Hold Post Q2 Earnings?

https://www.tradingview.com/news/stockstory:23a5ce1e9094b:0-dentsply-sirona-xray-buy-sell-or-hold-post-q2-earnings/
This article advises investors to avoid Dentsply Sirona (XRAY) despite a recent stock price drop, citing concerns over declining constant currency revenue, a downward trend in EPS, and negative returns on invested capital. The company's fundamentals are considered shaky, making its optically cheap valuation risky. The author suggests looking into other stock opportunities instead.

DENTSPLY SIRONA Q3 2026 Earnings Date and Estimates

https://www.marketbeat.com/earnings/reports/2026-11-5-dentsply-sirona-inc-stock/
DENTSPLY SIRONA (NASDAQ:XRAY) is projected to announce its Q3 2026 earnings on Thursday, November 5, 2026, after the market closes, with a conference call scheduled for 8:30 AM ET. Analysts anticipate earnings of $0.3125 per share on revenues of $862.76 million, which would represent a year-over-year decline compared to the $0.37 EPS and $904.00 million revenue reported in Q3 2025. The company's recent Q2 2026 report showed an EPS of $0.52, surpassing the consensus estimate.

DENTSPLY SIRONA on Track for Lowest Close Since March 2000 -- Data Talk

https://www.moomoo.com/news/post/1000618043/dentsply-sirona-on-track-for-lowest-close-since-march-2000
This article highlights that DENTSPLY SIRONA (XRAY) is on track for its lowest closing stock price since March 2000. It also notes that the stock's year-to-date performance places it among the worst in the S&P 500, with a significant decline in value.

Dentsply Sirona expands distribution deal with Midwest Dental By Investing.com

https://ng.investing.com/news/stock-market-news/dentsply-sirona-expands-distribution-deal-with-midwest-dental-93CH-2723854
Dentsply Sirona announced an expanded distribution agreement with Midwest Dental Equipment & Supply, effective November 1, 2026. This new deal allows Midwest Dental to distribute Dentsply Sirona’s full technology portfolio, including digital dentistry solutions, through its sales and service network in several southern U.S. states. This marks Dentsply Sirona's seventh North American dealer partnership enhancement in 2026, building on their previous consumables-focused relationship.

Dentsply Sirona Continues North American Commercial Expansion with Midwest Dental Agreement

https://www.globenewswire.com/de/news-release/2026/10/06/3375616/0/en/dentsply-sirona-continues-north-american-commercial-expansion-with-midwest-dental-agreement.html
Dentsply Sirona (Nasdaq: XRAY) has announced an expanded partnership with Midwest Dental Equipment & Supply, a family-owned dental distributor. Effective November 1, 2026, Midwest Dental will offer Dentsply Sirona’s technology portfolio in the United States, building on their existing consumables relationship. This agreement aims to broaden access to Dentsply Sirona's digital dentistry solutions and strengthen its North American dealer network.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement